Polypharmazie – Medikamente und QTc-Zeit. Was ist zu beachten?

Das erworbene Long-QT-Syndrom ist eine seltene Erkrankung. Allerdings ist die Inzidenz bei Patienten mit Polypharmazie deutlich erhöht. Das Risiko für QTc-Verlängerung als auch für Torsade-de-Pointes-Tachykardien wird durch die gleichzeitige Einnahme mehrerer QTc-Zeit-verlängernder Medikamente exponentiell größer. Dieser Artikel zeigt, welche Mechanismen hinter der Erkrankung stecken und wie das Risiko für potenziell tödliche Rhythmusstörungen gesenkt werden kann.

Schlüsselwörter

QTc-Zeit - Polypharmazie - Rhythmusstörungen

• Literatur

• 1 Marengoni A, Onder G. Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. BMJ 2015; 350: h1059 doi:10.1136/bmj.h1059
• 2 Hayes BD, Klein-Schwartz W, Barrueto F. Polypharmacy and the geriatric patient. Clin Geriatr Med 2007; 23: 371-390 vii doi:10.1016/j.cger.2007.01.002
• 3 Mosshammer D, Haumann H, Morike K. et al. Polypharmacy-an Upward Trend with Unpredictable Effects. Dtsch Ärztebl Int 2016; 113: 627-633 doi:10.3238/arztebl.2016.0627
• 4 Drew BJ, Ackerman MJ, Funk M. et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010; 121: 1047-1060 doi:10.1161/CIRCULATIONAHA.109.192704
• 5 De Bruin ML, Langendijk PN, Koopmans RP. et al. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs. Br J Clin Pharmacol 2007; 63: 216-223 doi:10.1111/j.1365-2125.2006.02722.x
• 6 Allen LaPointe NM, Curtis LH, Chan KA. et al. Frequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf 2006; 15: 361-368 doi:10.1002/pds.1155
• 7 Tisdale JE, Jaynes HA, Kingery JR. et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 2013; 6: 479-487 doi:10.1161/CIRCOUTCOMES.113.000152
• 8 Pratt CM, Ruberg S, Morganroth J. et al. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 1996; 131: 472-480 doi:10.1016/s0002-8703(96)90525-6
• 9 Zareba W. Drug induced QT prolongation. Cardiol J 2007; 14: 523-533
• 10 Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003; 24: 619-625 doi:10.1016/j.tips.2003.10.002
• 11 Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-1022 doi:10.1056/NEJMra032426
• 12 Roden DM. Taking the “idio” out of “idiosyncratic”: predicting torsades de pointes. Pacing Clin Electrophysiol 1998; 21: 1029-1034 doi:10.1111/j.1540-8159.1998.tb00148.x
• 13 Postema PG, De Jong JS, Van der Bilt IA. et al. Accurate electrocardiographic assessment of the QT interval: teach the tangent. Heart Rhythm 2008; 5: 1015-1018 doi:10.1016/j.hrthm.2008.03.037
• 14 Roguin A. Henry Cuthbert Bazett (1885–1950) – the man behind the QT interval correction formula. Pacing Clin Electrophysiol 2011; 34: 384-388 doi:10.1111/j.1540-8159.2010.02973.x
• 15 Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol 1993; 72: 17B-22B doi:10.1016/0002-9149(93)90035-b
• 16 Bogossian H, Frommeyer G, Ninios I. et al. New formula for evaluation of the QT interval in patients with left bundle branch block. Heart Rhythm 2014; 11: 2273-2277 doi:10.1016/j.hrthm.2014.08.026
• 17 Giudicessi JR, Noseworthy PA, Friedman PA. et al. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). Mayo Clin Proc 2020; 95: 1213-1221 doi:10.1016/j.mayocp.2020.03.024
• 18 Priori SG, Blomstrom-Lundqvist C, Mazzanti A. et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36: 2793-2867 doi:10.1093/eurheartj/ehv316
• 19 Al-Khatib SM, Stevenson WG, Ackerman MJ. et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72: e91-e220 doi:10.1016/j.jacc.2017.10.054
• 20 Pinski SL, Eguia LE, Trohman RG. What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers. Pacing Clin Electrophysiol 2002; 25: 1612-1615 doi:10.1046/j.1460-9592.2002.01612.x